Lupin and DKSH enter into an agreement for marketing five biosimilars in Philippines

7 Sep 2022 , 11:35 AM

Lupin Limited (Lupin) and DKSH, a prominent partner for healthcare firms looking to expand their business in Asia and beyond, announced the signing of an exclusive licensing and supply deal to commercialise five of Alvotech’s planned biosimilars in the Philippines.

This agreement calls for the development of biosimilars for Prolia (denosumab 60mg/ml), Xgeva (denosumab 70 mg/ml), Simponi (golimumab), and Eylea (aflibercept), as well as two unnamed potential biosimilars for immunology and oncology.

According to the agreement, Lupin’s subsidiary in the Philippines, Multicare Pharmaceuticals, would seek marketing clearance and will be responsible for the biosimilars’ distribution and commercialization if authorised.

“We are excited to add five additional biosimilar candidates to our portfolio, which will allow patients in the Philippines to have effective, high-quality, and economical treatment alternatives,” said Gabriel Georgy, Lupin’s Regional Head of Southeast Asia.

These reference products are used in the treatment of bone disease, cancer, immunology, and ophthalmology issues. This arrangement expands Multicare’s portfolio in cancer, rheumatology, gastrointestinal, and ophthalmology, which already includes three biosimilar candidates and more than 50 generic drugs.

At around 11.38 AM, Lupin was trading at Rs657.30 up by 0.67% from its previous closing of Rs652.90 on the BSE. The scrip opened at Rs647.05 and touched intraday high and low of Rs662 and Rs647.05 respectively.

For feedback and suggestions, write to us at [e-mail]